Trevi Therapeutics Inc (Nasdaq: TRVI), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has named Margaret Garin, MD, MSCR, as its new vice president of Clinical Development.

In the new role, Dr Garin will be responsible for advancing the clinical development of the company's Haduvio in chronic cough.

Dr Garin has more than 14 years of industry and academic research experience and more than nine years of global pharmaceutical industry experience in early and late-stage development. She has served as the executive director of Clinical Development at Bellus Health (now owned by GSK). She was the clinical development lead for programs in respiratory and inflammation at Teva Pharmaceuticals.